English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Because conventional anticoagulant doses of nonspecified source heparin used in myocardial ischemia had produced controversy, studies with larger doses of heparin from intestine and lung source were initiated. In dogs, control occlusion for 20 minutes of the left anterior coronary artery with epicardial electrocardiographic recordings, was followed after one hour of reperfusion with a second occlusion plus a 60,000 unit heparin infusion. The ischemic S-T segment elevations on control occlusions (64.5 ± 8.5 mV)were lowered 84% in intestinal heparin added occlusions (10.4 ± 3.0, p &lt; .00005). Lung heparin lowered S-T segments a lesser 36% (p &lt; .008). The difference between intestinal and lung heparin was significant (p &lt; .0007). Myocardial adenosine triphosphate levels at 90 minutes of occlusion were 31% higher in intestinal heparin dogs than in lung (p &lt; .01). At 24 hours, myocardial necrosis was 32% less, and myocardial creatine Phosphokinase levels were 15% higher, in dogs with 110,000 total units of intestinal heparin added, than in control dogs. Lung heparin has not been tested. Thus, large dose of both heparins significantly modified myocardial ischemia, and intestinal was significantly better than lung. Lung and intestinal heparin are probably functionally and structurally different. Then, in 18 acute myocardial infarction patients, anticoagulant doses of intestinal heparin significantly lowered S-T segments, but did not clearly improve cardiac enzyme levels. Optimal human heparin dose is probably larger than conventional anticoagulant dose. These studies may explain partially the controversy regarding heparin use in myocardial ischemia, and through increased dose of specific source heparin produce new therapy. They may eplain other paradoxical findings with heparin in other studies. More animal studies seem indicated prior to large dose heparin use in humans.

Heparin in Acute Myocardial Ischemia: Dose and Source Dependent Effects